AKR1C2 and ovarian cancer: In addition, Chen et al. [57] found an increase in AKR1C1, AKR1C2, AKR1C3 levels after a cisplatin administration for ovarian cancer, and Ueda et al. [58] documented the cisplatin-induced upregulation of AKR1C1, AKR1C2 in uterine cervical cancer.